Literature DB >> 21830637

Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease.

Nosratola D Vaziri1, Kaveh Navab, Pavan Gollapudi, Hamid Moradi, Madeleine V Pahl, Cyril H Barton, Alan M Fogelman, Mohamad Navab.   

Abstract

End-stage renal disease (ESRD) causes oxidative stress, inflammation, low-density lipoprotein (LDL) oxidation, high-density lipoprotein (HDL) deficiency and accelerated atherosclerosis. Uptake of oxidized LDL by macrophages results in foam cell and plaque formation. HDL mitigates atherosclerosis via reverse cholesterol transport and inhibition of LDL oxidation. ESRD heightens LDL inflammatory activity and suppresses HDL anti-inflammatory activity. The effect of hemodialysis on the LDL and HDL inflammatory properties is unknown. By removing the potential pro-oxidant/proinflammatory uremic toxins, dialysis may attenuate LDL inflammatory and HDL anti-inflammatory properties. Conversely, exposure to dialyzer membrane and tubing and influx of impurities from dialysate can intensify LDL and HDL inflammatory activities. This study examined the effect of hemodialysis on LDL and HDL inflammatory activities. Plasma samples were obtained from 12 normal control and 26 ESRD patients before and after hemodialysis with (16 patients) or without (10 patients) heparinization. HDL and LDL were isolated and tested for monocyte chemotactic activity in cultured endothelial cells. ESRD patients had increased LDL chemotactic activity, reduced HDL anti-inflammatory activity, paraoxonase and glutathione peroxidase levels, and elevated plasma IL-6 before dialysis. Hemodialysis partially improved LDL inflammatory and HDL anti-inflammatory activities and enhanced patients' HDL ability to suppress their LDL inflammatory activity. The salutary effect on LDL inflammatory activity was significantly greater in patients dialyzed with than those without heparin. ESRD heightens LDL inflammatory and impairs HDL anti-inflammatory activities. Hemodialysis partially improves LDL and HDL inflammatory activities. The salutary effects of hemodialysis are in part mediated by heparin, which is known to possess lipolytic and antioxidant properties.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21830637      PMCID: PMC3276406          DOI: 10.1016/s0027-9684(15)30368-0

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  45 in total

1.  Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein.

Authors:  A D Watson; J A Berliner; S Y Hama; B N La Du; K F Faull; A M Fogelman; M Navab
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

2.  Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure.

Authors:  N D Vaziri; G Deng; K Liang
Journal:  Nephrol Dial Transplant       Date:  1999-06       Impact factor: 5.992

3.  Down-regulation of VLDL receptor expression in chronic experimental renal failure.

Authors:  N D Vaziri; K Liang
Journal:  Kidney Int       Date:  1997-03       Impact factor: 10.612

4.  Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure.

Authors:  N D Vaziri; X Q Wang; K Liang
Journal:  Am J Physiol       Date:  1997-12

5.  Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure.

Authors:  N D Vaziri; K Liang
Journal:  Kidney Int       Date:  1996-12       Impact factor: 10.612

6.  Effect of serum subfractions from peritoneal dialysis patients on Hep-G2 cell apolipoprotein A-I and B metabolism.

Authors:  G M Shah; Z L Lin; V S Kamanna; R Pai; B Bassa; F Y Jin; D D Roh; M L Kashyap; M A Kirschenbaum
Journal:  Kidney Int       Date:  1996-12       Impact factor: 10.612

7.  Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study.

Authors:  Paul Muntner; Jiang He; Brad C Astor; Aaron R Folsom; Josef Coresh
Journal:  J Am Soc Nephrol       Date:  2004-12-29       Impact factor: 10.121

8.  Lipolytic effect of low-molecular-weight-heparin (Fragmin) and heparin/dihydroergotamine in thromboprophylactic doses during total hip replacement.

Authors:  T Myrmel; T S Larsen; O Reikerås
Journal:  Scand J Clin Lab Invest       Date:  1992-11       Impact factor: 1.713

9.  The effect of heparin on Cu(2+)-mediated oxidation of human low-density lipoproteins.

Authors:  R Albertini; S Rindi; A Passi; G Palladini; G Pallavicini; G De Luca
Journal:  FEBS Lett       Date:  1995-12-18       Impact factor: 4.124

10.  The heparin-binding domain of extracellular superoxide dismutase C and formation of variants with reduced heparin affinity.

Authors:  J Sandström; L Carlsson; S L Marklund; T Edlund
Journal:  J Biol Chem       Date:  1992-09-05       Impact factor: 5.157

View more
  13 in total

Review 1.  The effect of chronic kidney disease on lipid metabolism.

Authors:  Neris Dincer; Tuncay Dagel; Baris Afsar; Adrian Covic; Alberto Ortiz; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2018-12-05       Impact factor: 2.370

2.  Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients.

Authors:  Tae Ik Chang; Elani Streja; Melissa Soohoo; Tae Woo Kim; Connie M Rhee; Csaba P Kovesdy; Moti L Kashyap; Nosratola D Vaziri; Kamyar Kalantar-Zadeh; Hamid Moradi
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-13       Impact factor: 8.237

3.  Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients.

Authors:  Yasunori Suematsu; Masaki Goto; Christina Park; Ane C F Nunes; WangHui Jing; Elani Streja; Connie M Rhee; Siobanth Cruz; Moti L Kashyap; Nosratola D Vaziri; Vasanthy Narayanaswami; Kamyar Kalantar-Zadeh; Hamid Moradi
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

Review 4.  Statins in the management of dyslipidemia associated with chronic kidney disease.

Authors:  Murray Epstein; Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

5.  Dialysis Modalities and HDL Composition and Function.

Authors:  Michael Holzer; Gernot Schilcher; Sanja Curcic; Markus Trieb; Senka Ljubojevic; Tatjana Stojakovic; Hubert Scharnagl; Chantal M Kopecky; Alexander R Rosenkranz; Akos Heinemann; Gunther Marsche
Journal:  J Am Soc Nephrol       Date:  2015-03-05       Impact factor: 10.121

6.  Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients?

Authors:  Anna Gluba-Brzózka; Beata Franczyk; Maciej Banach; Magdalena Rysz-Górzyńska
Journal:  Int Urol Nephrol       Date:  2016-12-09       Impact factor: 2.370

7.  Paraoxonase 1 in chronic kidney failure.

Authors:  Alejandro Gugliucci; Kazuhiko Kotani; Satoshi Kimura
Journal:  J Lipids       Date:  2012-03-07

Review 8.  Eicosapentaenoic Acid as a Potential Therapeutic Approach to Reduce Cardiovascular Risk in Patients with End-Stage Renal Disease on Hemodialysis: A Review.

Authors:  Kenneth M Borow; R Preston Mason; Krishnaswami Vijayaraghavan
Journal:  Cardiorenal Med       Date:  2017-09-16       Impact factor: 2.041

Review 9.  New Pandemic: Obesity and Associated Nephropathy.

Authors:  Isha Sharma; Yingjun Liao; Xiaoping Zheng; Yashpal S Kanwar
Journal:  Front Med (Lausanne)       Date:  2021-06-29

10.  Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease.

Authors:  David J Kennedy; W H Wilson Tang; Yiying Fan; Yuping Wu; Shirley Mann; Michael Pepoy; Stanley L Hazen
Journal:  J Am Heart Assoc       Date:  2013-04-04       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.